Band3/CD233抗体;Band3/CD233 Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of Band 3 / CD233 expression in Red blood cell lysate.    

  
  

Band3. also known as CD233 or anion exchanger 1 (AE1), is a transmembrane glycoprotein encoded by the SLC4A1 gene. It is predominantly expressed on the surface of erythrocytes, where it plays a critical role in gas exchange by facilitating the chloride-bicarbonate exchange, thereby maintaining cellular pH and CO₂ transport. Structurally, Band3 consists of two domains: a N-terminal cytoplasmic domain that anchors the cytoskeleton to the membrane, and a C-terminal membrane-spanning domain responsible for ion transport.

Antibodies targeting Band3/CD233 are widely used in research and diagnostics. In hematology, they help identify erythrocyte membrane abnormalities linked to hereditary disorders like hereditary spherocytosis or Southeast Asian ovalocytosis. Band3 is also implicated in autoimmune hemolytic anemia, where autoantibodies disrupt erythrocyte integrity, leading to premature cell destruction. Additionally, Band3 serves as a receptor for Plasmodium falciparum in malaria pathogenesis, making it a potential therapeutic target.

In cancer research, Band3 expression has been observed in certain solid tumors, though its role remains unclear. Anti-Band3 antibodies are essential tools for studying erythrocyte aging, as clustered Band3 proteins signal for phagocytic removal of senescent red blood cells. These antibodies are typically generated in mice or rabbits and validated via flow cytometry, Western blot, or immunofluorescence. Their versatility underscores Band3’s physiological importance and relevance in disease mechanisms.